Monday, January 18, 2021
Home Health Covid-19: Oxford-AstraZeneca coronavirus vaccine approved for use in UK

Covid-19: Oxford-AstraZeneca coronavirus vaccine approved for use in UK

By James Gallagher
Health and science correspondent

image copyrightReuters

The coronavirus vaccine designed by scientists at the University of Oxford has been approved for use in the UK.

It will lead to a massive expansion in the UK’s immunisation campaign – aimed at getting life back to normal.

Health Secretary Matt Hancock said the rollout will start on 4 January “and will really accelerate into the first few weeks of next year”.

The UK has ordered 100 million doses from the manufacturer AstraZeneca – enough to vaccinate 50 million people.

The approval, by the medicines regulator, means the vaccine is both safe and effective.

The Oxford-AstraZeneca vaccine was designed in the first months of 2020, tested on the first volunteer in April, and has since been through large-scale clinical trials involving thousands of people.

  • Oxford vaccine: How did they make it so fast?

  • Concern at ‘unprecedented’ English infection level

It has been developed at a pace that would have been unthinkable before the pandemic.

It is the second jab to be approved in the UK after the Pfizer-BioNTech vaccine was given the go-ahead in December.

More than 600,000 people in the UK have been vaccinated since Margaret Keenan became the first in the world to get that jab outside of a clinical trial.

But the Oxford-AstraZeneca vaccine will lead to a significant increase in vaccination as it is cheap and easy to mass produce.

Crucially it can be stored in a standard fridge – unlike the Pfizer-BioNTech jab which needs ultra cold storage at -70C – so it will be far easier to get the Oxford vaccine to care homes and GP surgeries.

Priority groups for immunisation – including the elderly, care home residents and health and care workers – have already been identified.

The new vaccine approval comes after Public Health England said the country was facing “unprecedented” levels of infections, and health officials in parts of Wales, Scotland and the south of England voiced concerns about the increasing pressure on the NHS.

Who will get the vaccine?

The immunisation campaign will now shift to giving as many people as possible their first dose of vaccine.

The aim will be to give as many vulnerable people some protection from Covid-19.

The decision is based on advice from the Joint Committee on Vaccination and Immunisation.

A Department of Health and Social Care spokesperson said: “The priority should be to give as many people in at-risk groups their first dose, rather than providing the required two doses in as short a time as possible.

“Everyone will still receive their second dose and this will be within 12 weeks of their first. The second dose completes the course and is important for longer term protection.”

media captionLaura Foster explains how the vaccine works

How effective is the Oxford vaccine?

There are three figures doing the rounds – 62%, 70% and 90%.

The first analysis of the trial data showed 70% of people were protected from developing Covid-19 and nobody developed severe disease or needed hospital treatment.

The figure was just 62% when people were given two full doses of the jab and 90% when they were first given a half dose and then a full one.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved two full doses of the Oxford-AstraZeneca vaccine.

However, unpublished data suggests that leaving a longer gap between the first and second doses increases the overall effectiveness of the jab.

There was not enough clear data to approve the half-dose, full-dose idea.

All the vaccines are expected to be equally effective against the new variants of the virus that have emerged.

How does it work?

The vaccine is a genetically modified common cold virus that used to infect chimpanzees.

It has been altered to stop it causing an infection in people and to carry the blueprints for part of the coronavirus, known as the spike protein.

Once these blueprints are inside the body they start producing the coronavirus’ spike protein, which the immune system recognizes as a threat and tries to squash it.

Then, when the immune system comes into contact with the virus for real, it already knows what to do.

image captionTwo full doses of the Oxford vaccine gave 62% protection, a half dose followed by a full dose was 90% and overall the trial showed 70% protection.

Follow James on Twitter.

Do you have any questions about the coronavirus vaccine? Email haveyoursay@bbc.co.uk.

Or use this form to get in touch:

If you are reading this page and can’t see the form you will need to visit the mobile version of the BBC website to submit your comment or send it via email to HaveYourSay@bbc.co.uk. Please include your name, age and location with any comment you send in.

Related Topics

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Brooklyn Nets’ Kyrie Irving bought house for family of George Floyd, former NBA player Stephen Jackson says

Brooklyn Nets guard Kyrie Irving bought a house for the family of George Floyd, according to former NBA player Stephen Jackson.Jackson, who was a...

Ice Hockey World Championship: Belarus capital Minsk removed as host city on safety grounds

The International Ice Hockey Federation has said the 2021 World Championship will not be held in Minsk this year for safety and security reasons....

Tennis Kyrgios hits out at ‘tool’ Djokovic as tense Australian Open buildup continues

Nick Kyrgios joined former Davis Cup player Sam Groth in criticizing Novak Djokovic after the Serbian world No. 1 reportedly wrote to Australian Open...

Ghana president warns of health system overload as Covid cases soar

Ghana is not yet close to a peak seen during the first wave of infections in the middle of last year, but could quickly...

Recent Comments